Ayala Pharmaceuticals Inc (fka ADXS)

[fbg0316]

Load up. 2017 could be the year ADXS truly shines and reaches new all time highs as a result of clinical trial data emerging and additional deals (e.g., Merck next year, possibly Astra this year) helped by a tailwind of a more favorable biotech environment. The biotech sector is still down for the year in 2016, things could reverse nicely in 2017.

"$98 billion. That's the amount of cash U.S.-based pharma companies have parked overseas, according to the investment bank Jefferies. The majority of that cash could be repatriated in 2017 and used for acquisitions, if Trump follows through on a campaign promise. Giddiness over the prospect of a biotech M&A resurgence is the truer reason for Tuesday's stock rally, more so than drug pricing. If we start to see actual deals announced, this year's heavy underperformance in the biotech sector could be a fleeting memory rather quickly."